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ABSTRACT  
Fetuin-A, a hepatic-origin protein, is strongly positively associated with risk of type 2 
diabetes in human observational studies, but it is unknown whether this association is causal. 
We aimed to study the potential causal relation of circulating fetuin-A to risk of type 2 
diabetes in a Mendelian Randomization study with SNPs located in the fetuin-A-encoding 
AHSG gene. We used data from eight European countries of the prospective EPIC-InterAct 
case-cohort study including 10,020 incident cases. Plasma fetuin-A concentration was 
measured in a subset of 965 subcohort participants and 654 cases. A genetic score of the 
AHSG SNPs was strongly associated with fetuin-A (28% explained variation). Using the 
genetic score as instrumental variable of fetuin-A, we observed no significant association of a 
50 µg/ml higher fetuin-A concentration with diabetes risk (HR 1.02 [95%-CI 0.97, 1.07]). 
Combining our results with those from the Diabetes Genetics Replication And Meta-analysis 
(DIAGRAM) consortium (12,171 cases) also did not suggest a clear significant relation of 
fetuin-A with diabetes risk. In conclusion, although there is mechanistical evidence for an 
effect of fetuin-A on insulin sensitivity and secretion, this study doesn’t support a strong, 




Fetuin-A is a protein produced primarily by the liver, particularly in nonalcoholic fatty liver 
disease (1; 2). Fetuin-A is an inhibitor of the insulin receptor at the tyrosine kinase level (3; 4) 
Fetuin-A knockout mice were protected against insulin resistance (5; 6) and strong direct 
associations between fetuin-A levels and diabetes risk have been observed in prospective 
observational studies (7-13). 
 
Fetuin-A is encoded by the AHSG gene. Earlier studies have shown strong associations of 
AHSG SNPs with fetuin-A levels (14; 15). The Mendelian Randomization approach, which 
involves the use of genetic information as an instrumental variable of the exposure, can be 
applied to estimate the potential causal effect of fetuin-A on diabetes risk (16). So far, only 
one small study has applied the Mendelian randomization approach to investigate fetuin-A in 
relation to risk of type 2 diabetes (17). This study suggested no causal involvement of 
fetuin-A (17), however, it was limited by low power to detect associations. 
 
We therefore used data of the multicenter European Prospective Investigation into Cancer and 
Nutrition (EPIC)-InterAct study, with more than 10,000 incident cases of type 2 diabetes, to 
estimate the unconfounded effect of fetuin-A on diabetes risk with a Mendelian 
randomization approach. To maximize power, we additionally incorporated data from the 
Diabetes Genetics Replication And Meta-analysis (DIAGRAM) consortium involving further 
12,171 type 2 diabetes cases.   
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RESEARCH DESIGN AND METHODS 
EPIC-InterAct study 
The EPIC-InterAct study is a case-cohort study nested within the prospective EPIC study 
(18). In brief, EPIC includes 519,978 men and women, mostly aged 35-70 years, who were 
recruited between 1991 and 2000 at 23 centers in ten European countries participating in 
EPIC (19). Each EPIC center obtained individual written informed consent and local ethics 
approval. 
For the EPIC-InterAct study, incident cases of type 2 diabetes occurring in the EPIC cohort 
were ascertained and verified. All EPIC countries except Norway and Greece contributed to 
EPIC-InterAct (n=455,680). Individuals without stored blood (n=109,625) or without 
information on reported diabetes status (n=5,821) were excluded, leaving 340,234 participants 
eligible for inclusion in EPIC-InterAct (18). 
 
Case-cohort construction and case ascertainment 
A center-stratified, random subcohort of 16,835 individuals was selected. After exclusion of 
548 individuals with prevalent diabetes and 133 with uncertain diabetes status, the subcohort 
included 16,154 individuals for analysis (18). 
Details about the ascertainment of cases can be found in the supplemental material. 
Altogether, 12,403 verified incident cases were identified (18). In total, the EPIC-InterAct 
study involves 27,779 participants (16,154 subcohort members, 12,403 incident cases 
including 778 cases within the subcohort) (18). 
 
Study Population for the Present Analysis 
Figure 1 provides an overview of the study populations. As fetuin-A had been measured in 
Potsdam only, analyses involving fetuin-A were based on data of 1,593 participants from 
Potsdam (965 subcohort members, 654 incident cases including 26 cases within the 
7 
 
subcohort). Instrumental variable analysis was performed in the whole of EPIC-InterAct, 
excluding participants whose genetic data was not usable (n=5,287 due to insufficient amount 
of DNA, low call rate, X chromosome heterozygosity concordance with self-reported sex, 
outliers for heterozygosity, or lack of concordance with previous genotyping results) as well 
as EPIC-Potsdam participants with missing (n=16) or implausible (n=97) fetuin-A data, 
resulting in a dataset of 22,379 men and women (12,975 subcohort members, 10,020 incident 
cases). Analyses of the association of SNPs with potential confounders or mediators were 
performed after further exclusion of individuals (n=3,946) with missing values for these 
variables (dataset of 18,433 participants with 10,850 subcohort members and 8,108 cases). 
 
Measurement of Fetuin-A and Other Biomarkers 
Blood samples were taken at baseline. For the Potsdam participants, plasma levels of fetuin-A 
were measured in Tübingen, Germany, with the automatic ADVIA 1650 analyzer (Siemens 
Medical Solutions, Erlangen, Germany). An immunoturbidimetric method was used with 
specific polyclonal goat antihuman fetuin-A antibodies to human fetuin-A (BioVendor 
Laboratory Medicine, Modreci, Czech Republic). This method was evaluated in a side-by-
side comparison with an ELISA (intra-assay CV: 3.5%,  inter-assay: CV 5.4%, BioVendor) 
showing a correlation of r=0.93.  
All other laboratory measures were done for all EPIC-InterAct participants by the Stichting 
Huisartsen Laboratorium Groep (Etten-Leur, the Netherlands, see Supplemental Material).  
 
Genotyping, Identification of Tagging SNPs, and Construction of Genetic Scores 
Details about genotyping methods can be found in the Supplemental material. 
We selected five tagging SNPs of the AHSG gene (rs4917, rs2070635, rs2070633, rs2248690, 
rs4831) using HapMap 22/phaseII CEPH population data applying stringent criteria (minor 
allele frequency >5%, pairwise r2≥0.80) as similarly done earlier (14). A genetic score was 
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created by summing the number of fetuin-A-raising alleles of the single SNPs. We also 
constructed a weighted genetic score to account for the different strength of association 
between SNPs and fetuin-A (details of instrumental variables described in the Supplemental 
Material). 
 
Assessment of Other Covariables 
Standardized questionnaires were used at baseline to collect information on sociodemographic 
characteristics and lifestyle including age, education level, smoking status, occupational and 
leisure-time physical activity, and history of previous illness. Height, weight, and waist 
circumference of participants were obtained by trained staff during the baseline examination 
using standardized protocols (20). However, for participants from France and some 
participants from Oxford (UK), self-reported anthropometric data were collected. 
 
Statistical Analysis  
The associations of SNPs with fetuin-A were determined by linear regression in the Potsdam 
subcohort with SNPs modeled per fetuin-A-increasing allele (additive model). First, the 
individual SNPs were analyzed in separate models. Then, all SNPs were included in the same 
model. SNPs showing a significant association with fetuin-A in this model were used to 
generate the genetic scores, with beta coefficients used as weights.  
The associations of the genetic score with potential confounders or mediators were evaluated 
by linear regression for continuous and logistic regression for dichotomous 
confounders/mediators. 
To study the association of genetic variables with diabetes, we performed Cox regression with 
Prentice weighting (21). Age was used as underlying time scale. Models were stratified by 
integers of age (years), study center, and genotyping source and further adjusted for sex. 
Heterogeneity between countries in the association of the genetic variables with diabetes risk 
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was investigated by computing country-specific hazard ratios and pooling these with random-
effects meta-analyses. 
We calculated instrumental variable estimates to estimate the unconfounded effect of an 
increase of 50µg/ml in fetuin-A on diabetes risk. We assumed very similar associations of 
AHSG SNPs and fetuin-A concentration between the Potsdam center and the other EPIC-
InterAct centers and applied the two-stage least squares (2-SLS) procedure (22) for 
calculating instrumental variable estimates. 
To increase power, we further included data from the DIAGRAM consortium (see 
Supplemental Material). Summary statistics were meta-analyzed with the OR and 95% CI of 
the respective SNP derived from EPIC-InterAct (after excluding the Norfolk center because 
this is included in DIAGRAM) using a fixed-effect model. 
Statistical analyses were performed with SAS (version 9.4, Enterprise Guide 6.1; SAS 
Institute, Cary, NC, USA). 
Furthermore, we performed a power calculation using the online tool mRnd 





Table 1 shows baseline characteristics for the subcohort members of the EPIC-InterAct study 
and of the Potsdam center. 
 
Observational analysis of fetuin-A and diabetes risk 
In EPIC-Potsdam, circulating fetuin-A was positively associated with diabetes, with a HR of 
1.18 (95% CI: 1.05, 1.33) per 50 µg/ml in the multivariable-adjusted model (Supplemental 
Table 4). Additional adjustment for BMI and waist circumference did not alter the observed 
association. 
 
Association of AHSG SNPs and genetic scores with fetuin-A and diabetes risk 
In the Potsdam subcohort, four of the five AHSG SNPs were significantly associated with 
fetuin-A in univariate analyses (Supplemental Table 1). Including all five SNPs 
simultaneously in one model revealed significant associations for three SNPs (Table 2), which 
were subsequently used to create the genetic scores. Both the weighted (weighted by beta 
coefficients from linear regression) and the unweighted genetic score showed a strong 
association with fetuin-A explaining 28% and 27% of variation in fetuin-A, respectively. Both 
genetic scores were not associated with diabetes risk (Supplemental Figures 1, 2). 
We detected no meaningful association of the weighted genetic score with potential 
confounders or mediators in the EPIC-InterAct subcohort (Supplemental Tables 2, 3). 
 
Instrumental variable analysis of fetuin-A and diabetes 
Using instrumental variable analysis to estimate the unconfounded association for a 50µg/ml 
higher fetuin-A level did not indicate an effect on diabetes risk in EPIC-InterAct. The HR for 
the weighted genetic score was 1.02 (95% CI 0.97, 1.07). Also for single SNPs, the HRs were 
generally very low in magnitude (between 1.01 and 1.04) and nonsignificant (Table 3). When 
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further combining EPIC-InterAct with DIAGRAM, the ORs for the single SNPs remained the 
same, but ORs for two SNPs became borderline significant (OR for rs4917=1.02 [95% CI 
1.00, 1.06], OR for rs2248690=1.04 [95% CI 1.00, 1.08]). 
 
We also analyzed potential differences in the association of the weighted genetic score with 
diabetes risk in EPIC-InterAct. Stratification by age, sex, waist circumference, or HbA1c did 





In this large European case-cohort study, instrumental variables reflecting circulating fetuin-A 
were not significantly associated with diabetes risk. Further meta-analyzing results with those 
from the DIAGRAM consortium to bolster statistical power also did not indicate a strong 
association of genetically-elevated fetuin-A with diabetes. 
 
Several prospective observational studies have detected a significant and strong positive 
association between plasma fetuin-A levels and the risk of type 2 diabetes (7-13). We could 
not confirm this strong association in a Mendelian Randomization approach. Although we 
found borderline significant estimates for two SNPs (OR for rs4917=1.02 [95% CI 1.00, 
1.06], OR for rs2248690=1.04 [95% CI 1.00, 1.08]), our results do not suggest a strong causal 
association because an allele increase corresponds to a high difference in fetuin-A (50µg/ml, 
SD for fetuin-A=61µg/ml). According to our results of the observational analysis, we would 
have expected an OR of 1.18. Due to the use of different assays to determine concentrations 
of fetuin-A across studies, we could not calculate expected ORs based on the other 
observational studies on fetuin-A and diabetes risk. the slightly stronger associations of 
AHSG SNPs with fetuin-a (17) than in EPIC-Potsdam and results of quantile comparisons (7-
9; 11; 12) suggest even higher expected ORs based on these studies. 
 
 Our study was not designed to unravel specific factors that explain the results of earlier 
observational studies, but it suggests that fetuin-A concentration more strongly reflects an 
adverse metabolic profile than being an important causal risk factor in the pathogenesis of 
diabetes. 
 
Our results are in agreement with those from an earlier small study on AHSG SNPs and 
diabetes risk involving older adults (17). Fetuin-A was positively associated with fasting 
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glucose levels, but AHSG SNPs did not support an association between genetically predicted 
fetuin-A concentrations and fasting glucose or diabetes risk. A major limitation of this study 
is the small study size resulting in a low power for the instrumental variable analysis (3,435 
participants including 259 incident cases). 
 
In experiments of mice and human adipocytes, it has been observed that free fatty acids 
(FFAs) require the presence of fetuin-A to induce an inflammatory signaling pathway 
resulting in insulin resistance and subclinical inflammation (24). Fetuin-A might indeed 
contribute to the development of type 2 diabetes in already predisposed individuals with high 
concentrations of FFAs. Supporting this assumption, an interaction of fetuin-A and FFAs in 
determining insulin sensitivity was observed in a study of 347 participants at increased risk 
for type 2 diabetes and CVD (25). In our study, the unavailability of FFA blood 
concentrations precluded us from investigating a potential effect modification by FFAs.  
 
A major strength of our study relates to the large sample size for analyzing AHSG SNPs and 
genetic scores in relation to diabetes risk. AHSG SNPs and genetic scores showed strong 
associations with circulating fetuin-A resulting in powerful instrumental variables. All SNPs 
are located in the fetuin-A-encoding AHSG gene, making pleiotropic roles of the SNPs rather 
unlikely. As limitation, we have information on circulating fetuin-A only in the Potsdam 
center of EPIC-InterAct.  
 
In conclusion, although there is mechanistical evidence for an effect of fetuin-A on insulin 
sensitivity and secretion, this study does not support a strong, relevant relationship between 
circulating fetuin-A and diabetes risk in the general population. 
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Table 1 - Baseline characteristics of subcohort participants of the EPIC-InterAct study 
(n=10,850) and the Potsdam center (n=965) 
 EPIC-InterAct  Potsdam center  
General characteristics   
Age, years 53 (9) 50 (9) 
Male 37 39 
BMI (kg/m2) 26.1 (4.2) 25.7 (4.1) 
Current smoking 27 19 
Physically active 21 16 
Longer education 21 38 
Alcohol intake (g/d)  7.4 (1.2, 20.1) 8.2 (3.1, 19.5) 
   
Biomarkers   
Fetuin-A, µg/ml - 267 (61) 
GGT, U/l  20 (14, 32) 21 (15, 35) 
ALT, U/l  18 (14, 25) 19 (14, 27) 
Albumin, g/l 46 (3) 46 (3) 
Creatinine, umol/l  68 (60, 78) 69 (61, 80) 
CRP, mg/l 1.1 (0.6, 2.4) 1.1 (0.6, 2.3) 
HDL cholesterol, mmol/l 1.5 (0.4) 1.5 (0.4) 
Total cholesterol, mmol/l 6.0 (1.1) 5.9 (1.1) 
Triglycerides, mmol/l  1.1 (0.8, 1.7) 1.1 (0.8, 1.7) 
HbA1c, % (mmol/mol) 5.4 [5.2, 5.7] (36 [33, 39]) 5.4 [5.1, 5.5] (35 [32, 37]) 





Table 2 - Association of individual AHSG SNPs and genetic scores with fetuin-A 
concentration in the Potsdam part of the EPIC-InterAct study subcohort – 
Simultaneous adjustment of SNPs 
 Allele β (SE) for fetuin 
concentration 











rs2070635 G→A -0.6 (5.1) 0.9013  
rs2070633 T→C 23.7 (8.2) 0.0040  
rs2248690 T→A 12.3 (4.3) 0.0040  
rs4831 G→C 1.1 (8.6) 0.9008  
 
Genetic scores* 
    
Weighted score  52.4 (2.8) <0.0001 <0.0001 
Unweighted score  53.0 (2.8) <0.0001 <0.0001 
n=965 
β for individual SNPs obtained from one linear regression model including all five SNPs 
simultaneously, β for genetic scores obtained from single univariate linear regression models,  
SNPs and genetic scores modelled per fetuin-A-increasing allele and fetuin-A expressed in 
µg/ml  
*Genetic scores were created as sum of fetuin-A-increasing alleles of rs4917, rs2070633 and 
rs2248690, divided by three. Betas of the three SNPs from linear regression have been used as 





Table 3 - Instrumental variable estimates for the weighted genetic score and single 
AHSG SNPs reflecting the association of a 50µg/ml increase in fetuin-A concentration 




rs4917 rs2070633 rs2248690 
     
EPIC-InterAct* 1.02 (0.97, 1.07) 1.02 (0.98, 1.07) 1.01  (0.95, 
1.08) 
1.04  (0.96, 
1.10) 




 1.02  (1.00, 
1.06) 
1.01  (0.98, 
1.05) 
1.04  (1.00, 
1.08) 
Data are HRs (for EPIC-InterAct) or ORs (for EPIC-InterAct and DIAGRAM combined) and 
95% CIs per 50µg/ml increase in fetuin-A concentration. Instrumental variable estimates were 
obtained from two-stage least squares procedure. Estimates for EPIC-InterAct and 
DIAGRAM have been combined with a fixed-effects meta-analysis.  
* n=22,379 including 12,975 incident cases of type 2 diabetes 
† DIAGRAM: n=69,033 including 12,171 incident cases of type 2 diabetes  
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Figure 1   Construction of the EPIC-InterAct case-cohort study and the study populations 
used for the present analysis 
ONLINE SUPPLEMENTAL MATERIALS 
Case ascertainment 
Ascertainment of incident type 2 diabetes involved a review of the existing EPIC datasets at 
each center using multiple sources of evidence including self-report, linkage to primary-care 
registers, secondary-care registers, medication use (drug registers), hospital admissions and 
mortality data. Information from any follow-up visit or external evidence with a date later 
than the baseline visit was used. Rather than self-report, cases in Denmark and Sweden were 
identified via local and national diabetes and pharmaceutical registers and hence all 
ascertained cases were considered to be verified. Some cases in centers other than Denmark 
and Sweden were based on only one source of information. To increase the specificity of the 
definition for these cases, we sought further evidence including review of individual medical 
records in some centers. Follow-up was censored at the date of diagnosis, 31 December 2007 
or the date of death, whichever occurred first. 
 
Measurement of biomarkers (except fetuin-A) 
The measurements were performed on serum (except for participants in the Umeå center in 
Sweden, where only plasma samples were available) or erythrocyte samples that had been 
previously frozen in liquid nitrogen or at ultra-low-temperature freezers at -80°C (samples 
from Umea, Sweden). γ-glutamyltransferase (GGT), alanine transaminase (ALT), albumin, 
creatinine, C-reactive protein (CRP), high-density lipoprotein (HDL) cholesterol, total 
cholesterol, and triglycerides were measured using a Cobas® (Roche Diagnostics, Mannheim, 
Germany) assay on a Roche Hitachi Modular P analyzer. Erythrocyte HbA1c was measured 
using Tosoh (HLC-723G8) ion exchange high-performance liquid chromatography on a 
Tosoh G8 analyzer.  
 Genotyping 
DNA was extracted from buffy coat from a citrated blood sample using standard procedures 
on an automated Autopure LS DNA extraction system (Qiagen, Hilden, Germany) with 
PUREGENE chemistry (Qiagen). The DNA was hydrated overnight prior to further 
processing, quantified by PicoGreen assay (Quant-iT) and normalised to 50 ng/ µl. Samples 
were genotyped if they had sufficient DNA, could be successfully genotyped on Taqman or 
Sequenom platforms and had sex chromosome genotypes concordant with self-reported sex. 
Samples that failed one genotyping round were repeated in another if they failed for reasons 
that may not relate to sample quality (e.g. signal intensity outliers or plates/arrays with an 
unusually high failure rate). Samples to be genotyped on the Illumina 660 W-Quad BeadChip 
were randomly selected from the available samples with the number of individuals selected 
per center being proportional to the percentage of total cases in that center. Danish samples 
were not available at this stage. Genotyping was carried out at the Wellcome Trust Sanger 
Institute. The remaining samples were genotyped on either the Illumina HumanCoreExome-
12 or HumanCoreExome-24 at Cambridge Genomic Services in the University of Cambridge, 
Department of Pathology. 
Before imputation, SNPs were filtered to remove those with minor allele count < 2, call rate < 
95% or Hardy Weinberg p-value < 1e-6. SNPs were also removed if they were not found in 
the Haplotype Reference Consortium (HRC) panel, were A/T or G/C with MAF > 0.4, had an 
allele frequency difference > 0.2 with reference panel, or were indels. Imputation was 
performed at the Wellcome Trust Centre for Human Genetics using the HRC panel version 
1.0 and IMPUTE v2.3.2 software. 
 
Instrumental variable construction 
Unless variants are highly correlated, all variants which can be reasonably assumed to be 
valid instruments can be included in a Mendelian randomization analysis to improve the 
precision of the causal estimate (1). To account for the high correlation within the AHSG 
gene, we first identified tagging SNPs based on HapMap 22/phaseII CEPH population data 
applying stringent criteria (minor allele frequency >5%, pairwise r2≥0.80) as similarly done 
earlier (2). As this selection process does not rule out high intercorrelation, the five SNPs 
identified (rs4917, rs2070635, rs2070633, rs2248690, rs4831) were subsequently included in 
the same regression model and gene scores as instrumental variables were based on those 
SNPs showing a significant independent association with fetuin-A in this model. 
The recent GWAS by Jensen et al. (3) has identified several more SNPs to be univariately 
associated with fetuin-A levels. E.g. 5 SNPs showed very low p-values and were not in high 
LD with rs4917 in the GWAS (3). However, all 5 were well covered by rs2070633 (r2 ranging 
from 0.811 to 0.875 based on HapMap CEPH) selected for our gene score. Overall, the 
considerable degree of LD among SNPs in the AHSG gene, the magnitude of association of 
other SNPs identified in the GWAS (3) besides those mentioned above (substantially weaker 
compared to rs4917), and the statistical power of our instrumental variables (see below) 
makes it unlikely that inclusion of additional SNPs would substantially improve our 
instrumental variable approach. 
 
Meta-Analysis of DIAGRAM and EPIC-InterAct data 
We have used summary statistics of a meta-analysis consisting of 12,171 type 2 diabetes cases 
and 56,862 controls across 12 GWAS as published elsewhere (4). All studies participating in 
DIAGRAM included men and women of European descent. DIAGRAM data are publicly 
available at http://diagram-consortium.org/downloads.html. We extracted the odds ratio and 
corresponding 95% CIs for each of the three SNPs that were used to create the genetic scores 
(rs4917, rs2070633, rs2248690). 
 
Power calculation 
The power for the Mendelian Randomization analysis at a two-sided α of 0.05 was calculated 
based on the available sample size, the association of the genetic variables with fetuin-A 
concentration, and the expected causal effect estimate using the online tool mRnd 
(http://glimmer.rstudio.com/kn3in/mRnd/). 
Given the HR of 1.18 per 50 µg/ml higher fetuin-A in our observational analysis, we would 
have expected a HR of 1.19 per allele of the weighted genetic score based on the association 
of the genetic variables with fetuin-A concentration in the subcohort of the Potsdam center. In 
EPIC-InterAct, we have 99.9% power to detect this expected HR with the weighted genetic 
score or with the single SNPs (rs4917, rs2070633, and rs2248690). Combining our data with 
those from the DIAGRAM consortium further increased the power enabling us to detect a HR 
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Supplemental Table 1 - Association of individual AHSG SNPs with fetuin-A 





Mean level (µg/ml) 
of fetuin-A  
by AHSG genotype 




   11 12 22    
rs4917 T C 214 257 299 44.1 (2.6) 3.404573E-56 0.24 
rs2070635 A G 238 272 308 37.0 (2.6) 1.489007E-41 0.18 
rs2070633 T C 223 267 307 42.3 (2.5) 1.557487E-57 0.24 
rs2248690 T A 212 252 291 41.8 (2.9) 2.588671E-43 0.19 
rs4831 G C 270 267 272 4.0 (4.4) 0.3719 0.0009 
n=965 
β obtained from single univariate linear regression models for each SNP with SNPs modelled 
per fetuin-A-increasing allele and fetuin-A expressed in µg/ml  
  
Supplemental Table 2 - Association of weighted genetic score with potential confounders  
Continuous traits β (SE) p 
Age, years -0.26 (0.13) 0.05 
Alcohol intake, g/d  0.38 (0.30) 0.21 
GGT, U/l  0.49 (0.63) 0.44 
ALT, U/l  0.08 (0.21) 0.71 
Albumin, g/l -0.03 (0.05) 0.50 
Creatinine, umol/l  -0.17 (0.24) 0.49 
   
   
Binary traits Odds ratio (95% CI) p 
Sex, male 0.97 (0.91, 1.04) 0.41 
Current smoking  0.93 (0.87, 1.00) 0.06 
Physically active 1.01 (0.93, 1.09) 0.83 
Longer education  
(incl. university) 
0.94 (0.87, 1.02) 0.13 
β obtained from linear regression (age, alcohol intake, GGT, ALT, albumin, creatinine) and 
ORs obtained from logistic regression (sex, current smoking, physically active, longer 
education); estimates are per fetuin-A-increasing allele of the weighted genetic score, adjusted 
for country among 10,850 subcohort participants  
  
Supplemental Table 3 - Association of weighted genetic score with potential mediators 
Mediators (continuous) β (SE) p 
BMI, kg/m2 0.04 (0.06) 0.52 
Waist circumference, cm 0.19 (0.19) 0.33 
CRP, mg/l -0.06 (0.06) 0.38 
HDL cholesterol, mmol/l 0.0009 (0.007) 0.90 
Total cholesterol, mmol/l -0.03 (0.02) 0.12 
Triglycerides, mmol/l  -0.002 (0.01) 0.91 
HbA1c, mmol/mol  0.08 (0.08) 0.31 
β obtained from linear regression; estimates are per fetuin-A-increasing allele of the weighted 
genetic score, adjusted for country among 10,850 subcohort participants  
Supplemental Table 4– Instrumental variable estimates for the weighted genetic score in 
strata of age, sex, waist circumference, and HbA1c in the EPIC-InterAct study 
Strata HR (95% CI) per 50µg/ml increase in 
fetuin-A concentration 
Age≤55 years (n=11,953) 1.01 (0.92, 1.11) 
Age>55years (n=10,426) 1.04 (0.97, 1.10) 
  
Men (n=9,691) 1.03 (0.93, 1.13) 
Women (n=12,688) 1.03 (0.94, 1.11) 
  
Low waist circumference (n=10,450) (Men: 
≤98 cm, Women: ≤84 cm) 
1.01 (0.93, 1.10) 
High waist circumference (n=10,163) (Men: 
>98 cm, Women: >84 cm) 
1.02 (0.96, 1.09) 
  
HbA1c≤5.6% (38 mmol/mol) (n=12,064) 1.03 (0.93, 1.12) 
HbA1c>5.6% (38 mmol/mol) (n=9,865) 0.97 (0.89, 1.07) 
Instrumental variable estimates were obtained from two-stage least squares procedure. Data 
are adjusted for age, sex, study center, and genotyping source. Analyses have been performed 
stratified by country and combined with random-effects meta-analysis. 
 
  
 Supplemental Figure 1 – Forest plot of the association of the weighted genetic score with 
diabetes risk in the EPIC-InterAct study by country 
Data are HRs and 95% CIs per fetuin-A-increasing allele, adjusted for age, sex, study center, 
and genotyping source. Analyses have been performed stratified by country and combined 
with random-effects meta-analysis.  
n=22,379 including 12,975 incident cases of type 2 diabetes 
 
  
 Supplemental Figure 2 – Forest plot of the association of the unweighted genetic score 
with diabetes risk in the EPIC-InterAct study by country 
Data are HRs and 95% CIs per fetuin-A-increasing allele, adjusted for age, sex, study center, 
and genotyping source. Analyses have been performed stratified by country and combined 
with random-effects meta-analysis. 
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